Examples of using Non-inferiority in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Statistical non-inferiority was not achieved.
Similar efficacy for rilpivirine was seen in each trial demonstrating non-inferiority to efavirenz.
Immunologic non-inferiority to 7-valent Prevenar.
However, both analyses were compatible with a conclusion of non-inferiority between both treatment arms.
This study showed the non-inferiority of Xeomin(70-300 U) compared to Botox 70-300 U.
The hazard ratio for telmisartan vs. ramipril was 1.0197.5% CI 0.93- 1.10, p(non-inferiority) 0.0019 at a margin of 1.13.
The CHMP agreed that no non-inferiority study is required and the following wording for section 4.1 was adopted.
However, the study where Enurace 50 is compared to Propaline(ACE129802)is convincing although a non-inferiority analysis has not been performed.
The trial demonstrated non-inferiority of MabThera to cyclophosphamide for complete remission(CR) at 6 months Table 14.
The safety, efficacy and quality of life of pazopanib versus sunitinib has beenevaluated in a randomised, open-label, parallel group Phase III non-inferiority study VEG108844.
A lower bound greater than -15% demonstrates non-inferiority between Aloxi and comparator. c Chi-square test.
Non-inferiority was proven for adult patients, and similar findings were demonstrated for the paediatric subpopulations including neonates and premature infants.
Efficacy was based on demonstrating non-inferiority of intravenous palonosetron compared to intravenous ondansetron.
Non-inferiority was demonstrated between fosamprenavir co-administered with ritonavir and lopinavir/ ritonavir based on the proportions of patients achieving plasma HIV-1 RNA levels< 400 copies/ ml at 48 weeks primary endpoint.
In BRIGHTER, ranibizumab 0.5 mg with adjunctive laser therapy demonstrated non-inferiority versus ranibizumab monotherapy from baseline to Month 24 95% CI -2.8, 1.4.
In the non-inferiority study, V59P6, immunogenicity was assessed among adolescents aged 11-17 years who had been randomised to receive either Menveo or ACWY-PS.
Copies/ml, with PREZISTA/ritonavir 800/100 mg once daily treatment was demonstrated to be non-inferior(at the pre-defined 12% non-inferiority margin) compared to PREZISTA/ritonavir 600/100 mg twice daily for both ITT and OP populations.
An open label, randomised, Phase III non-inferiority study compared the efficacy and safety of the subcutaneous administration of VELCADE versus the intravenous administration.
However, in patients with liver iron concentration< 7 mg Fe/ g dw treated with EXJADE(5 and 10 mg/ kg) ordeferoxamine(20 to 35 mg/ kg), non-inferiority was not established due to imbalance in the dosing of the two chelators.
The non-inferiority criterion was met for both PFS and OS with the upper bound of the 95% confidence interval for the associated hazard ratios being less than 1.176 Table 13.
It appeared from a post-hoc analysis of this study that, in the subgroup of patients with liver iron concentration≥ 7 mg Fe/ g dw treated with EXJADE(20 and 30 mg/ kg) ordeferoxamine(35 to≥ 50 mg/ kg), the non-inferiority criteria were achieved.
A To report analysis of primary endpoint(Ctrough non-inferiority) for Part 2 and available safety and immunogenicity data from both parts of the ongoing study.
Non-inferiority in HbA1c change from baseline to end-of-trial was confirmed in all studies against all comparators, when treating patients to target.
The safety and efficacy profiles of the two Enbrel treatment regimens were comparable at week 8 in their effect on signs and symptoms of RA;data at week 16 did not show comparability(non-inferiority) between the two regimens.
The study showed non-inferiority of 6 mg lipegfilgrastim to 6 mg pegfilgrastim for the primary endpoint, duration of severe neutropenia(DSN) in the first cycle of chemotherapy see table 2.
However, in patients with liver iron concentration< 7 mg Fe/g dw treated with deferasirox dispersible tablets(5 and 10 mg/kg) ordeferoxamine(20 to 35 mg/kg), non-inferiority was not established due to imbalance in the dosing of the two chelators.
The non-inferiority immune response comparisons for study 006, based on the proportion of infants achieving anti-polysaccharide IgG concentrations≥ 0.35 μg/ml, are shown in Table 1.
Micafungin(100 mg/day or 2 mg/kg/day) was as effective as and better tolerated than liposomal amphotericin B(3 mg/kg) as first-line treatment of candidaemia and invasive candidiasis in a randomised, double-blind,multinational non-inferiority study.
Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival in the eligible patient population and the intent-to-treat population see Table 7.
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke[0.99(97.5% CI 0.90- 1.08),p(non-inferiority) 0.0004], the primary endpoint in the reference study HOPE(The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.